Skip to content
Homepage
Author:
Onco3R Therapeutics BV
Posted Date:
May 25, 2026
Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline
Onco3R Therapeutics BV
May 25, 2026
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Onco3R Therapeutics BV
February 20, 2026
